Psoriatic Arthritis (PsA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Psoriatic Arthritis (PsA) Market Outlook

Thelansis’s “Psoriatic Arthritis (PsA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Psoriatic Arthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Psoriatic Arthritis (PsA) Overview

Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory condition primarily affecting the joints and the areas where tendons and ligaments connect to bones. It typically co-occurs with a skin condition known as psoriasis. Enthesitis is among its most common distinguishing features. Other clinical manifestations include joint swelling, painful and itchy red patches, and the accumulation of silvery dead skin cells. PsA can also impact the sacroiliac joint of the pelvic region and the spine, resulting in stiffness in the neck and back. The precise cause of psoriatic arthritis remains unknown. It usually emerges in individuals between 30 and 50, although it can begin as early as childhood. Both genders are equally susceptible to PsA, and its genetic epidemiology sets it apart. PsA has been linked to human leukocyte antigen (HLA) class 1 allele, compared to rheumatoid arthritis (RA), associated with HLA class 2 alleles. Notably, PsA presents distinct extra-articular manifestations compared to RA, with the absence of rheumatoid nodules. While rheumatoid factor is detected in over 80% of RA patients, it is found in only about 13% of individuals with PsA.

• The incidence of Psoriatic arthritis (PsA) is estimated to be 2.9 per 100 PsO patient-years.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: